| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SUCLG2 |
| Uniprot No | Q96I99 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 49-423aa |
| 氨基酸序列 | MSDNGVRVQRFFVADTANEALEAAKRLNAKEIVLKAQILAGGRGKGVFNSGLKGGVHLTKDPNVVGQLAKQMIGYNLATKQTPKEGVKVNKVMVAEALDISRETYLAILMDRSCNGPVLVGSPQGGVDIEEVAASNPELIFKEQIDIFEGIKDSQAQRMAENLGFVGPLKSQAADQITKLYNLFLKIDATQVEVNPFGETPEGQVVCFDAKINFDDNAEFRQKDIFAMDDKSENEPIENEAAKYDLKYIGLDGNIACFVNGAGLAMATCDIIFLNGGKPANFLDLGGGVKEAQVYQAFKLLTADPKVEAILVNIFGGIVNCAIIANGITKACRELELKVPLVVRLEGTNVQEAQKILNNSGLPITSAIDLEDAAK |
| 预测分子量 | 56.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SUCLG2重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Functional Characterization of Recombinant SUCLG2 in Mitochondrial Energy Metabolism"*
**作者**：Zhang Y et al. (2015)
**摘要**：研究通过在大肠杆菌中表达并纯化人源SUCLG2重组蛋白，验证其作为琥珀酸辅酶A合成酶β亚基的催化活性，发现其与SUCLG1亚基结合后显著增强线粒体ATP合成效率。
2. **文献名称**：*"SUCLG2 Recombinant Protein Interacts with Metabolic Enzymes in Tumor Cells"*
**作者**：Wang L et al. (2018)
**摘要**：利用重组SUCLG2蛋白进行蛋白质相互作用筛选，发现其与糖酵解关键酶(如HK2)存在直接结合，提示SUCLG2可能在肿瘤细胞代谢重编程中协调TCA循环与糖酵解途径。
3. **文献名称**：*"Crystal Structure of Human SUCLG2 Reveals Substrate Binding Mechanism"*
**作者**：Chen X et al. (2020)
**摘要**：首次解析了SUCLG2重组蛋白的晶体结构，阐明其与底物琥珀酸和辅酶A的结合位点，为遗传性线粒体疾病相关突变的功能研究提供结构基础。
(注：以上文献信息为示例性质，实际引用需以真实发表文献为准。)
**Background of SUCLG2 Recombinant Protein**
SUCLG2 (succinate-CoA ligase GDP-forming subunit beta) is a critical component of the mitochondrial enzyme succinyl-CoA synthetase (SCS), which plays a central role in the tricarboxylic acid (TCA) cycle and mitochondrial energy metabolism. This enzyme catalyzes the reversible conversion of succinate and CoA into succinyl-CoA, coupled with substrate-level phosphorylation of GDP to GTP (or ADP to ATP, depending on isoform composition). SUCLG2 forms a heterodimer with the alpha subunit (SUCLG1) to constitute the GDP-specific SCS isoform (SCS-GDP), which is predominantly expressed in tissues with high energy demands, such as liver, heart, and brain.
Recombinant SUCLG2 protein is engineered through heterologous expression systems (e.g., *E. coli* or mammalian cells*) to study its structural, functional, and regulatory properties. Its production enables detailed investigation of mitochondrial disorders linked to SUCLG2 mutations, such as encephalomyopathy, metabolic acidosis, and Leigh-like syndromes. Additionally, SUCLG2 dysfunction is implicated in cancer metabolism, as altered TCA cycle activity supports tumor proliferation under hypoxic conditions.
The recombinant protein serves as a tool for elucidating enzymatic mechanisms, screening inhibitors, and developing diagnostic assays. Studies leveraging SUCLG2 recombinant proteins have advanced understanding of mitochondrial substrate-level phosphorylation, metabolic flexibility, and diseases associated with impaired succinyl-CoA metabolism. Its role in connecting the TCA cycle to mitochondrial GTP production also highlights its importance in cellular bioenergetics and biosynthesis pathways, including heme and amino acid metabolism.
Overall, SUCLG2 recombinant protein is vital for both basic research and translational studies targeting mitochondrial dysfunction and metabolic diseases.
×
